Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human randomized placebo-controlled ascending-dose study of LNP1955 in healthy volunteers
NL-OMON42416Phase 1Active, not recruiting
- Sponsor
- Lupin Limited
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Inflammatory Disorders and rheumatoid arthritis (RA) comparing LNP1955 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started May 2015; status: active, not recruiting.
02
Drugs
LNP1955
03
Conditions
Inflammatory Disordersrheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON42416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42416.